MLYS - NASDAQ

Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc.

MLYS·NASDAQ

$25.06

-19%
HealthcareBiotechnology

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$1.66B
EPS-2.2900
P/E Ratio-10.94
Earnings Date08/11/2026

Available Earnings Call Transcripts

Select a year and quarter to view the full transcript.

Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc. Earnings Call Transcripts

MLYS · NASDAQ

Related Guides

Blog Categories

Continue your MLYS research with focused valuation guides.

Forecasting

Compare management guidance with modeled outcomes.

Risk Analysis

Track estimate risk, misses, and downside scenarios.

Reference

Review analyst process and transcript interpretation.

Value Investing

Anchor quarterly narrative to intrinsic value discipline.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.